Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hermansky-Pudlak syndrome with pulmonary fibrosis as a complication includes two types (HPS-1 and HPS-4) of Hermansky-Pudlak syndrome (HPS), a multi-system disorder characterized by oculocutaneous albinism, bleeding diathesis and, in some cases, pulmonary fibrosis or granulomatous colitis.
Biomarker and diagnostic research for Hermansky-Pudlak syndrome with pulmonary fibrosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Hermansky-Pudlak syndrome with pulmonary fibrosis.
38 publications have been identified in PubMed for Hermansky-Pudlak syndrome with pulmonary fibrosis. Research spans Case Report / Case Series (37%), Basic Science / Preclinical (29%), and Review / Meta-Analysis (21%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 14 | 37% |
Data assembled from 3 of 12 sources · Last updated Sep 21, 2026, 4:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Hermansky-Pudlak syndrome with pulmonary fibrosis
Laboratory research
11 |
29% |
Research summaries | 8 | 21% |
Testing and diagnosis research | 3 | 8% |
Other research | 1 | 3% |
New treatment approaches | 1 | 3% |
Giulianelli G (2026). [PMID: 42125657](https://pubmed.ncbi.nlm.nih.gov/42125657/). *Front Immunol*. [Case Report / Case Series]
Li X (2026). [PMID: 41953037](https://pubmed.ncbi.nlm.nih.gov/41953037/). *Front Immunol*. [Case Report / Case Series]
Pezet MG (2026). [PMID: 39994483](https://pubmed.ncbi.nlm.nih.gov/39994483/). *Nat Biotechnol*. [Basic Science / Preclinical]
Arif M (2026). [PMID: 40720784](https://pubmed.ncbi.nlm.nih.gov/40720784/). *Am J Respir Cell Mol Biol*. [Diagnostic / Biomarker]
Sabelhaus T (2026). [PMID: 41911684](https://pubmed.ncbi.nlm.nih.gov/41911684/). *Rofo*. [Case Report / Case Series]
Ghincea A (2026). [PMID: 40737518](https://pubmed.ncbi.nlm.nih.gov/40737518/). *Am J Respir Cell Mol Biol*. [Basic Science / Preclinical]
Chen S (2026). [PMID: 41909159](https://pubmed.ncbi.nlm.nih.gov/41909159/). *JCEM Case Rep*. [Case Report / Case Series]
Liu Q (2025). [PMID: 41277635](https://pubmed.ncbi.nlm.nih.gov/41277635/). *Ther Adv Respir Dis*. [Review / Meta-Analysis]
Alcidi R (2025). [PMID: 40308332](https://pubmed.ncbi.nlm.nih.gov/40308332/). *Case Rep Med*. [Case Report / Case Series]
Tondi F (2025). [PMID: 40387003](https://pubmed.ncbi.nlm.nih.gov/40387003/). *IUBMB Life*. [Review / Meta-Analysis]